Leerink Swann Downgrades AVEO Pharmaceuticals (AVEO) to Market Perform, Cites Tivozanib Risks
Tweet Send to a Friend
Leerink Swann downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Outperform to Market Perform with a price target of $10.00 (from $12.00).
This article: 179 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 179 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
